DOCSLIB.ORG

Information to Users

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Information to Users INFORMATION TO USERS This manuscript has been reproduced from the microfihn master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type o f computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6” x 9” black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. UMI A Bell & Howell Infomiation Company 300 North Zed) Road, Ann Arbor MI 48106-1346 USA 313/761-4700 800/521-0600 i j DEVELOPMENT OF DRUGS FOR HUMAN PROSTATE CANCER DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Chiung-Tong Chen, M.S. ***** The Ohio State University 1997 Dissertation Committee: Approved by Dr. M. Guillaume Wientjes, Adviser Dr. Jessie L.-S. Au Dr. William L. Hayton Adviser Dr. Kenneth K. Chan College of Pharmacy UMI Number: 9813235 UMI Microform 9813235 Copyright 1998, by UMI Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. UMI 300 North Zeeb Road Ann Arbor, Ml 48103 ABSTRACT Prostate cancer represents a growing public health problem in the United States and Europe. In 1997, an estimate of 43% of total newly diagnosed cancers (334.500 new cases) in men were adenocarcinomas of the prostate, the most frequent malignancy in men currently. Fifteen to twenty-five percent of newly diagnosed cases had been reported as advanced stages o f diseases. The benefit o f survival from currently available treatment is minimal. It is projected that 41,800 men will die of prostate cancer in the United States in 1997. Progress in the understanding of prostate tumor biology and the development of effective therapy has been hampered by lack of clinically relevant tumor models. The work presented in this dissertation focused on the development of clinically relevant prostate tumor models for drug activity evaluation, and on the evaluation of pharmacologic effects of two anticancer agents in human prostate tumors. The major conclusions and contributions of the research in this dissertation are as follows: (a) The establishment of pharmacodynamics of paclitaxel (Chapter 2) and doxorubicin (Chapter 4) in histocultures of patient and three human xenograft tumors (Chapter 7). These data indicate that paclitaxel and doxorubicin are active against early stage and androgen dependent prostate cancer, with the antiproliferative effect being more prominent than the cytotoxic (i.e., cell kill) effect. It is noted that these results are the first to delineate the two effects separately, (b) The apoptotic effect of paclitaxel in patient tumors in their native 3-dimensional state is cell cycle specific (Chapter 3). These results confirm the previously reported cell cycle specificity of paclitaxel-induced apoptosis in monolayer cultures o f human cancer cells, and indicate that the microenvironment of solid tumors do not alter this property of paclitaxel effect, (c) the concentrations of doxorubicin delivered to prostate tissue in dogs, after an intravenous injection, are insufiBcient to deliver the concentrations needed to produce >50% antiproliferation and cytotoxicity, respectively, in patient tumors (Chapters 5 and 6). These results demonstrate that insufficient drug delivery to tumors is one cause of the lack of clinical response, and have led to the development of regional therapy where the drug is delivered in high concentrations directly to the prostate, (d) The CWR22, CWR22R and CWR91 human prostate xenograft tumors show pharmacodynamics of paclitaxel and doxorubicin that are qualitatively and quantitatively similar to those in patient tumors (Chapter 7). It is noted that these models are the first to show responses to drugs similar to patient tumors; other models such as monolayer cultures of human cancer cells overpredict chemosensitivity by >10 fold. These results establish the three xenograft tumors as clinically relevant models for drug activity evaluation. As discussed in Chapter 8, Conclusions and Perspectives, the results described in this dissertation has led to several avenues of research in our laboratory that focus on the development of new effective treatments for prostate cancer, a deadly disease with few treatment options. Ill Dedicated to my parents and families IV ACKNOWLEDGMENTS I would like to express my most sincere gratitude to my adviser Dr. Wientjes for his considerate and supportiveness throughout this study. The completion of this study encompasses 5 years of my efforts at The Ohio State University. With as much sincerity, I am grateful to Dr. Au for the her advises and her intimate collaboration with Dr. Wientjes, from which intellectual interactions have been built upon and critical scientific demanding drove me toward being mature mind of sciences. I wish to thank my advisory committee members, Drs. William L. Hayton and Kenneth K. Chan, for helpful advisory discussions. I want to thank Dr. Gan, Y. and Lu, J. for technical support and sharing study materials and results; Drs. Yen, J., Kuh, H-J., Kuan, H.Y., and Johnson, A. and Millenbaugh, N., and Jang, S.H. for stimulating discussions; Dr. Koo, P., Johnston, J., Kellough, D A., Jones, W., Jurcisek, J., Lembach, M., Koolemans-Beynen, A., and Cai, J. for technical support. Friendships from others in the laboratory and the college have been appreciated. Special thanks to my parents, parents-in-law and families for their long-term supports in every way. Supports from my wife and the duty as a father have been the motives and joys that help me through. VITA December 4, 1962 ......................................... Bom - Taiwan, Republic of China 1986 ................................................................. B.S. in Pharmacy, China Medical College 1988 ................................................................. M.S. in Pharmacology, National Yang-Ming Medical College 1990- 1991....................................................... Vice Researcher, Shu-Lin Research Center, China Chemical & Pharmaceutical Group 1990 - 1991....................................................... Registered Pharmacist 1992 ................................................................. Assistant Research Fellow, Institute of Biological Chemistry, Academia Sinica 1992 - present ................................................. Graduate Research Associate, The Ohio State University PUBLICATIONS Papers 1. Chen, C.T., Au, J.L.-S., Gan, Y.B., and Wientjes, M.G. Differential time dependency of antiproliferative and apoptotic effects of taxol in human prostate tumors. Urol. Oncol., 3: 11-17, 1997. 2. Ho, C.L., Lin, Y.L., Chen, W.C., Yu, H.M., Wang, K.T., Hwang, L.L., and Chen, C.T. Immunogenicity of mastoparan B, a cationic tetradecapeptide isolated from the hornet (Vespa basalis) venom, and its structural requirements. Toxicon, VI 33:1443-1451, 1995. 3. Ho, C.L., Hwang, L.L., Lin, Y.L., Chen, C.T., Yu, H.M., and Wang, K.T. Cardiovascular effects of mastoparan B and its structural requirements. Eur. J. Pharmacol., 259:259-264, 1994. 4. Ho, C.L., Hwang, L.L., and Chen, C.T. Edema-inducing activity of a lethal protein with phospholipase A, activity isolated from the black-bellied hornet (Vespa basalis) Venom. Toxicon, 31:605-613, 1993. 5. Chen, C.T., Chan, J.Y.H., Barnes, C.D., and Chan, S.H.H. Tonic suppression of baroreceptor reflex by endogenous neurotensin in the rat. Regul. Peptides, 28:23-37, 1990. Abstracts 1. Gan, Y., Au, J.L.-S., Chen, C.T., and Wientjes, M.G. Cytotoxicity of suramin, geldanamycin, cytochalasin E, and tfiiacetazone in human prostate cancer xenografts. Proc. Am. Assoc. Cancer Res., 38:219, 1997. 2. Au, J.L.-S., Li, D., Gao, X., Gan, Y , Chen, C.T., Ge, S., Johnson, A.L., and Wientjes, M.G. Time-dependent taxol cytotoxicity. Proc. Am. Assoc. Cancer Res., 38:4, 1997. 3. Au, J.L.-S., Li, D., Gao, X., Gan, Y , Chen, C.T., Yen, W.C., Johnson, A.L., and Wientjes, M.G. Time-dependent taxol effect in human and rat solid tumors. Archives of Otolaryngology-Head and Neck Surgery, 4th International Conference on Head and Neck Cancer, 493:193, 1996. 4. Chen, C.T., Gan, Y.B., Au, J.L-S., and Wientjes, M.G. Response of human prostate tumors to taxol: Relationship with expression of multidrug resistance p- glycoprotein and bcl-2. Proc. Am. Assoc. Cancer Res., 37:368, 1996. 5. Weaver, J R., Kalns, J.E., Schmittgen, T.D., Chen, C.T., Lim, C., and Au, J.L.-S. Molecular pharmacodynamic endpoints for antiproliferative agents. Proc. Am. Assoc. Cancer Res., 36:360, 1995. vn 6. Gan, Y.B., Balturshot, G., Millenbaugh, N.E., Chen, C.T., Kalns, J.E., Lim, C , and Wientjes, M.G., Au, J.L.-S. P-glycoprotein expression in human tumors and its correlation with chemosensitivity to taxol and cell mobility. Proc. Am. Assoc. Cancer Res., 36:334, 1995. 7. Chen, C.T., Au, J.L-S., Burgers, J.K., and Wientjes, M.G. Comparative activity of taxol and doxorubicin in human prostate tumors. Proc. Am. Assoc. Cancer Res. 36:320, 1995. 8. Chen, C.T., Au, J.L-S., Burgers, J.K., and Wientjes, M.G. Pharmacodynamics of taxol in human prostate tumors.
Load more

Recommended publications
  • Cumulative Contents, 1983
    Cumulative Contents, 1983 Volume 47, No.1 January 1983 I STEEL, G.G., COURTENAY, V.D. & OXFORD LYMPHOMA GROUP. Prognostic PECKHAM, M.J. The response to chemotherapy factors in non-Hodgkins lymphoma: The of a variety of human tumour xenografts. importance of symptomatic stage as an adjunct to the Kiel histopathological classification. 15 STRUCK, R.F., DYKES, D.J., CORBETT, T.H., SULING, W.J. & TRADER, M.W. 103 TRENT, J.M., DAVIS, J.R. & DURIE, B.G.M. Isophosphoramide mustard, a metabolite of Cytogenetic analysis of leukaemic colonies from ifosfamide with activity against murine tumours acute and chronic myelogenous leukaemia. comparable to cyclophosphamide. Ill CHILD, J.A., CRAWFORD, S.M., NORFOLK, 27 MUINDI, J.R.F., NEWELL, D.R., SMITH, I.E. D.R., O'QUIGLEY, J., SCARFFE, J.H. & & HARRAP, K.R. Pentamethylmelamine STRUTHERS, L.P.L. Evaluation of serum beta (PMM): Phase I clinical and pharmacokinetic 2-microglobulin as a prognostic indicator in studies. myelomatosis. 35 FORD, C.H.J., NEWMAN, C.E., JOHNSON, 115 EL-DEEB, B.B., BURNS, S., ROBINSON, R., J.R., WOODHOUSE, C.S., ROWLAND, G.F., HAMMOND, E.M. & MANN, J.R. Serum SIMMONDS, R.G. & REEDER, T.A. dopamine-,B-hydroxylase in children with Localisation and toxicity study of a vindesine neuroblastoma. anti-CEA conjugate in patients with advanced cancer. 123 BINDON, C., CZERNIECKI, M., RUELL, P.. EDWARDS, A., McCARTHY, W.H.. 43 EMBLETON, M.J., ROWLAND, G.F., HARRIS, R. & HERSEY, P. Clearance of rates SIMMONDS, R.G., JACOBS, E., MARSDEN, and systematic effects of intravenously C.H. & BALDWIN, R.W.
    [Show full text]
  • Induction of Dormancy in Hypoxic Human Papillomavirus-Positive Cancer Cells
    Induction of dormancy in hypoxic human papillomavirus-positive cancer cells Karin Hoppe-Seylera, Felicitas Bosslera, Claudia Lohreya, Julia Bulkeschera, Frank Röslb, Lars Jansenc, Arnulf Mayerd, Peter Vaupeld, Matthias Dürstc, and Felix Hoppe-Seylera,1 aMolecular Therapy of Virus-Associated Cancers (F065), German Cancer Research Center, D-69120 Heidelberg, Germany; bViral Transformation Mechanisms (F030), German Cancer Research Center, D-69120 Heidelberg, Germany; cDepartment of Gynecology, Jena University Hospital, D-07743 Jena, Germany; and dDepartment of Radiooncology and Radiotherapy, Mainz University Medical Center, D-55131 Mainz, Germany Edited by Karl Münger, Tufts University School of Medicine, Boston, MA, and accepted by Editorial Board Member Peter K. Vogt December 19, 2016 (received for review September 21, 2016) Oncogenic human papillomaviruses (HPVs) are closely linked to major (17), is considered to play a major role in tumor development and human malignancies, including cervical and head and neck cancers. It progression. Clinically, hypoxia can increase the resistance to is widely assumed that HPV-positive cancer cells are under selection chemotherapy and radiotherapy and is a negative prognostic pressure to continuously express the viral E6/E7 oncogenes, that their marker for many cancers, including HPV-positive tumors (15, 16, intracellular p53 levels are reconstituted on E6/E7 repression, and that 18–20). Notably, although O2 availability is known to affect tumor E6/E7 inhibition phenotypically results in cellular senescence. Here we cell biology (14–16), most functional studies of the HPV E6/E7 show that hypoxic conditions, as are often found in subregions of oncogenes in cervical cancer cells have been performed under cervical and head and neck cancers, enable HPV-positive cancer cells to standard cell culture conditions at 21% O2.
    [Show full text]
  • The Role of Pik3ca in Head and Neck Cancer Progression
    THE ROLE OF PIK3CA IN HEAD AND NECK CANCER PROGRESSION by XI CHEN B.S., The University of Denver, 2010 A thesis submitted to the Faculty of the Graduate School of the University of Colorado in partial fulfillment of the requirements for the degree of Doctor of Philosophy Cancer Biology Program 2016 This thesis for Doctor of Philosophy degree by Xi Chen has been approved for the Cancer Biology Program by Rebecca Schweppe, Chair Mary Rayland Lynn Heasley Heide Ford Maranke Koster Shi-long Lu, Advisor Date: December 16, 2016 ii Xi Chen (Ph.D., Cancer Biology) The Role of PIK3CA in Head and Neck Cancer Progression Thesis directed by Professor Shi-long Lu ABSTRACT Head and neck squamous cell carcinoma (HNSCC) patients have a poor prognosis, with invasion, recurrence and metastasis as major causes of mortality. Currently, effective therapeutic options for advanced HNSCCs are still limited. The phosphatidylinositol 3-kinase (PI3K) pathway regulates a wide range of cellular processes crucial for tumorigenesis, and PIK3CA amplification and mutation are among the most common genetic alterations in HNSCC. Compared to the well- documented roles of the PI3K pathway in cell growth and survival, its roles in tumor invasion, recurrence and metastasis have not been well delineated. Herein, I used a PIK3CA-genetically engineered mouse model (PIK3CA- GEMM) in which PIK3CA is overexpressed in head and neck epithelium to mimic PIK3CA amplification in human HNSCC patients. I found that PIK3CA overexpression increased tumor invasiveness and metastasis by increasing de- differentiation and epithelial-to-mesenchymal transition (EMT), and marked inflammation in tumor stroma.
    [Show full text]
  • Combined Inhibition of Mtor and Pikks Exploits Replicative and Checkpoint Vulnerabilities to Induce Death of PI3K-Activated Triple-Negative Breast Cancer Cells
    bioRxiv preprint doi: https://doi.org/10.1101/700625; this version posted July 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Combined inhibition of mTOR and PIKKs exploits replicative and checkpoint vulnerabilities to induce death of PI3K-activated triple-negative breast cancer cells Sameer S. Chopra,1,3,5 Anne Jenney,1,3 Adam Palmer,1,3 Mario Niepel,1,3 Mirra Chung,1,3 Caitlin Mills,1,3 Sindhu Carmen Sivakumaren,2,5 Qingsong Liu,2,5 Jia-Yun Chen,1 Clarence Yapp,1,3 John M. Asara,4 Nathanael S. Gray,2,5 Peter K. Sorger1,3* 1Laboratory of Systems Pharmacology, 2Dept. of Biological Chemistry and Molecular Pharmacology, 3Harvard Ludwig Center, 4Division of Signal Transduction, Beth Israel Deaconess Medical Center, 5Dana-Farber Cancer Institute Harvard Medical School, 200 Longwood Avenue, Boston, MA 02215 *Corresponding: [email protected] Page 1 bioRxiv preprint doi: https://doi.org/10.1101/700625; this version posted July 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. SUMMARY Frequent mutation of genes in the PI3K/AKT/mTOR signaling pathway in human cancers has stimulated large investments in therapeutic drugs but clinical successes have been rare.
    [Show full text]
  • Mistletoe Therapy
    The Journal of IHP – Continuing Education SUCCESSFUL COMPLETION OF THE QUESTIONS AT THE END OF THIS PAPER HAS BEEN APPROVED FOR CONTINUING EDUCATION BY THE BDDT-N; 1.0 CREDIT PARENTAL THERAPY AND BY THE CNPBC; ONE CE HOUR. Mistletoe Therapy Improving Outcomes In Complementary Cancer Care By Sarah Vanderheyden, RPN and Heidi Fritz, MA, ND Sarah Vanderheyden, RPN ABSTRACT: 8 Leland Road, London, ON N6K Mistletoe therapy is an herbal medicine best known for its role in complementary 1T1 cancer care. Pioneered by Rudolf Steiner, mistletoe, also known as Viscum album L or European mistletoe, has its roots in anthroposophic medicine; today there is Heidi Fritz, MA, ND a large body of evidence supporting use of mistletoe injection therapy as an Bolton Naturopathic Clinic, adjunctive cancer treatment. Lectins and viscotoxins found in mistletoe appear to 64 King Street West, Bolton, ON, L7E 1C7 www. be responsible for its antitumor and immune stimulating effects. Mistletoe boltonnaturopathic.ca therapy has been investigated for its effects on survival, quality of life, and tolerability of chemotherapy/ side effects associated with chemotherapy. Meta analyses and systematic reviews have demonstrated a survival benefit associated with use of mistletoe injection therapy alongside chemotherapy or as a supportive therapy. There is also a large body of evidence indicating that mistletoe therapy improves quality of life, with improvements in global quality of life as well as symptoms such as fatigue, nausea and vomiting, pain, sleep disturbances, loss of appetite, and constipation found in a preliminary study. Finally, mistletoe therapy appears to reduce side effects of chemotherapy without decreasing its effectiveness.
    [Show full text]
  • Inhibition of Calcium-Independent Phospholipase A2 Induces
    INHIBITION OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2 INDUCES PROSTATE CANCER CELL CYTOSTASIS by BIN SUN (Under the Direction of Brian S. Cummings) ABSTRACT The goal of this work was to identify mechanisms by which inhibition of calcium- independent phospholipase A2 (iPLA2) induces cytostasis in human LNCaP (p53 wild-type and androgen-sensitive) and PC-3 (p53 negative and androgen-insensitive) prostate cancer cells. Both the iPLA2 selective inhibitor bromoenol lactone (BEL) and iPLA2 siRNA induced cytostasis. Cytostasis correlated to a G1/G0 arrest in LNCaP cells and a G2/M arrest in PC-3 cells. In LNCaP cells, G1 arrest was preceded by increases in tumor suppresser protein p53 and p21. In contrast, neither p53 nor p21 was detectable in PC-3 cells, suggesting that BEL activates p21 independently of p53. Further, the iPLA2 selective inhibitor S-BEL had greater affects on cytostasis, phosphorylated (P)-p53 (Ser15), p53 and p21 expression than the iPLA2 inhibitor R- BEL, suggesting that iPLA2 plays more important roles in cytostasis and p53/p21 epxression than iPLA2. BEL decreased cell growth correlated to activation of p38MAPK in both cells. In contrast, BEL only transiently induced ERK in PC-3 cells but not in LNCaP and did not activate JNK in either cell line. Pharmacological inhibition of p38 inhibited BEL-induced increases in P- p53 (Ser15), p53 and p21 as well as G1 arrest in LNCaP cells. BEL treatment also induced reactive species (RS) in PC-3 and LNCaP cells. The antioxidant NAC inhibited BEL-induced RS, p38, p53 and cytostasis in LNCaP cells and attenuated BEL induced RS and cytostasis in PC-3 cells, supporting the hypothesis that RS mediated cytostasis induced by iPLA2 inhibition.
    [Show full text]
  • Prerequisites for the Antitumor Vaccine-Like Effect Of
    Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy Dalil Hannani, Antonella Sistigu, Oliver Kepp, Lorenzo Galluzzi, Guido Kroemer, Laurence Zitvogel To cite this version: Dalil Hannani, Antonella Sistigu, Oliver Kepp, Lorenzo Galluzzi, Guido Kroemer, et al.. Prereq- uisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy. Cancer Journal, Lippincott, Williams & Wilkins, 2011, 17, 10.1097/PPO.0b013e3182325d4d. hal-02047421 HAL Id: hal-02047421 https://hal.archives-ouvertes.fr/hal-02047421 Submitted on 17 Dec 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy Dalil Hannani, PhD,* †§ Antonella Sistigu, PhD,* †§ II Oliver Kepp, PhD,*þ§ Lorenzo Galluzzi, PhD,*þ§ Guido Kroemer, MD, PhD,*þ¶L**ÞÞ and Laurence Zitvogel, MD, PhD*Þ§ From the *Institut Gustave Roussy, Villejuif, France; †INSERM, U1015, Villejuif, France; ‡INSERM, U848, Villejuif, France; §Universite´ Paris Sud-XI, Villejuif, France; ||Istituto Superiore di Sanita`, Rome, Italy; ¶Metabolomics Platform, Institut Gustave Roussy, Villejuif, France; LCentre de Recherche des Cordeliers, Paris, France; **Pôle de Biologie, Hooˆpital Europe´en Georges Pompidou, Paris, France; ††Universite´ Paris Descartes, Paris, France. Correspondance: Laurence Zitvogel, MD, PhD, INSERM, U1015, Institut Gustave Roussy, F-94805 Villejuif, Paris, France.
    [Show full text]
  • Elucidating Mechanisms of Innate and Acquired Resistance to Pi3ka Inhibition in Head and Neck Squamous Cell Carcinoma Kara M
    Western University Scholarship@Western Electronic Thesis and Dissertation Repository November 2018 Elucidating mechanisms of innate and acquired resistance to PI3Ka inhibition in head and neck squamous cell carcinoma Kara M. Ruicci The University of Western Ontario Supervisor Nichols, Anthony C. The University of Western Ontario Graduate Program in Pathology A thesis submitted in partial fulfillment of the requirements for the degree in Doctor of Philosophy © Kara M. Ruicci 2018 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Oncology Commons Recommended Citation Ruicci, Kara M., "Elucidating mechanisms of innate and acquired resistance to PI3Ka inhibition in head and neck squamous cell carcinoma" (2018). Electronic Thesis and Dissertation Repository. 5788. https://ir.lib.uwo.ca/etd/5788 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected], [email protected]. Abstract The phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signalling pathway is aberrantly activated in most head and neck squamous cell carcinomas (HNSCCs). PI3K signalling drives cellular proliferation, protein synthesis and cell survival. Although numerous targeted agents are available to inhibit PI3K signalling, results have been variable and factors influencing response to PI3K inhibition (e.g. genomic aberrations, pathway interconnectivity, acquired drug resistance) are not well defined. In this thesis, we employ a multifaceted approach to elucidate the molecular underpinnings of biomarkers of response and mediators of resistance to PI3K inhibition in HNSCC.
    [Show full text]
  • 17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractoryadvanced Cancers Ramesh K
    Cancer Therapy: Clinical Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with RefractoryAdvanced Cancers Ramesh K. Ramanathan,1, 3 Donald L.Trump,1, 3 Julie L. Eiseman,1,4 Chandra P. Belani,1, 3 SanjivS. Agarwala, 1, 3 Eleanor G. Zuhowski,1Jing Lan,1 Douglas M. Potter,2 S. Percy Ivy,5 Sakkaraiappan Ramalingam,1, 3 Adam M. Brufsky,1, 3 Michael K.K.Wong,1, 3 SusanTutchko,1and MerrillJ. Egorin1, 3,4 Abstract Purpose: 17-(Allylamino)-17-demethoxygeldanamycin (17AAG), a benzoquinone antibiotic, down-regulates oncoproteins by binding specifically to heat shock protein 90 (HSP90). We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize17AAG pharmacokinetics and pharmacodynamics. Experimental Design: Escalating doses of 17AAG were given i.v. over1or 2 hours on a weekly  3 schedule every 4 weeks to cohorts of three to six patients. Plasma pharmacokinetics of 17AAGand17-(amino)-17-demethoxygeldanamycin (17AG) were assessed by high-performance liquid chromatography. Expression of HSP70 and HSP90 in peripheral blood mononuclear cells was measured byWestern blot. Results: Forty-five patients were enrolled to 11dose levels between 10 and 395 mg/m2.The maximum tolerated dose was 295 mg/m2. Dose-limiting toxicity occurred in both patients (grade 3 pancreatitis and grade 3 fatigue) treated with 395 mg/m2. Common drug-related toxicities (grade1and 2) were fatigue, anorexia, diarrhea, nausea, and vomiting. Reversible elevations ofliver enzymes occurredin 29.5% of patients. Hematologic toxicity was minimal.
    [Show full text]
  • The Changing Pattern of Management for Hormone-Refractory, Metastatic Prostate Cancer
    Prostate Cancer and Prostatic Diseases (2006) 9, 221–229 & 2006 Nature Publishing Group All rights reserved 1365-7852/06 $30.00 www.nature.com/pcan REVIEW The changing pattern of management for hormone-refractory, metastatic prostate cancer ND James1, D Bloomfield2 and C Luscombe3 1Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK; 2Sussex Oncology Centre, Royal Sussex County Hospital, Brighton, UK and 3Department of Urology, University Hospital of North Staffordshire, Stoke-on-Trent, Staffordshire, UK Prostate cancer responds initially to hormonal manipulation by androgen withdrawal and peripheral androgen blockade. The inevitable progression to a hormone-refractory state is accompanied by an exacerbation of local symptoms and metastatic spread, principally to the bones, which has a considerable impact on quality of life and survival. Treatment of hormone- refractory prostate cancer is palliative, and surgery and radiotherapy are used for the relief of lower urinary tract symptoms and localized painful bony metastases. Systemic treatments are not widely accepted in this setting, but clinical trials have demonstrated the potential for bone targeting agents such as strontium-89 and the bisphosphonates to palliate painful bone metastases and to delay progression in certain settings. Chemotherapy with mitozantrone in combination with steroids has previously been shown to have palliative benefits and to delay progression. The additional costs incurred by the use of chemotherapy or bone-targeting therapies may be offset by gains in overall care with fewer in-patient admissions compared with steroid monotherapy . Recent clinical trials have demonstrated that docetaxel significantly improves patient quality of life, and importantly, increases survival. Future studies investigating the timing of chemotherapy, combinations with existing treatments or other novel therapies are underway.
    [Show full text]
  • The Novel Dual PI3K/Mtor Inhibitor GDC-0941 Synergizes with the MEK Inhibitor U0126 in Non-Small Cell Lung Cancer Cells
    MOLECULAR MEDICINE REPORTS 5: 503-508, 2012 The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells ZU-QUAN ZOU1*, LI-NA ZHANG1*, FENG WANG2, JÉRÔME BELLENGER3, YIN-ZHUO SHEN1 and XIAO-HONG ZHANG1 1Medical School, Ningbo University; 2Clinical Laboratory, Lihuili Hospital, Ningbo 315211, P.R. China; 3UMR 866 Physiopathologie des Dyslipidémies, Faculté des Sciences Gabriel, Université de Bourgogne, Dijon, France Received May 25, 2011; Accepted August 22, 2011 DOI: 10.3892/mmr.2011.682 Abstract. Lung cancer is a malignant disease with poor outcome, witnessed targeted therapy in NSCLC. However, gefitinib, a which has led to a search for new therapeutics. The PI3K/Akt/ specific inhibitor of epidermal growth factor receptor (EGFR) mTOR and Ras/raf/Erk pathways are key regulators of tumor tyrosine kinase, has shown efficacy only in a subgroup of growth and survival. In the present study, their roles were NSCLC patients with EGFR mutations and overexpression. It evaluated by MTT assay, flow cytometry and Western blotting was previously shown that EGFR-independent activation of the in lung cancer cells. We found that a high efficacy of antitumor PI3K/Akt/mammalian target of rapamycin (mTOR) and Ras/ activity was shown with GDC-0941 treatment in two gefitinib- raf/Erk pathways may contribute to the unfavorable treatment resistant non-small cell lung cancer (NSCLC) cell lines, A549 outcome of gefitinib (2). and H460. In addition, H460 cells with activating mutations The PI3K/Akt/mTOR and Ras/raf/Erk signaling pathways of PIK3CA were relatively more sensitive to GDC-0941 than play a key role in cell growth, proliferation and survival in a A549 cells with wild-type PIK3CA.
    [Show full text]
  • Phase I Pharmacokinetic and Pharmacodynamic Study of 17
    VOLUME 23 ⅐ NUMBER 18 ⅐ JUNE 20 2005 JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies Udai Banerji, Anne O’Donnell, Michelle Scurr, Simon Pacey, Sarah Stapleton, Yasmin Asad, Laura Simmons, Alison Maloney, Florence Raynaud, Maeli Campbell, Michael Walton, Sunil Lakhani, Stanley Kaye, Paul Workman, and Ian Judson From the Cancer Research UK Centre for Cancer Therapeutics, The Institute ABSTRACT of Cancer Research; Section of Medi- cine, The Institute of Cancer Research; Purpose The Royal Marsden Hospital, Sutton; To study the toxicity and pharmacokinetic-pharmacodynamic profile of 17-allylamino, 17- Cancer Research UK, Drug Development demethoxygeldanamycin (17-AAG) and to recommend a dose for phase II trials. Office; and Breakthrough Breast Cancer Research Centre, Institute of Cancer Patients and Methods Research, London, United Kingdom. This was a phase I study examining a once-weekly dosing schedule of 17-AAG. Thirty patients with advanced malignancies were treated. Submitted November 30, 2004; accepted January 18, 2005. Results 2 Supported by Cancer Research UK. The highest dose level reached was 450 mg/m /week. The dose-limiting toxicities (DLTs) encountered were grade 3 diarrhea in three patients (one at 320 mg/m2/week and two at 450 Presented in part at the 37th Annual 2 2 Meeting of the American Society of mg/m /week) and grade 3 to 4 hepatotoxicity (AST/ALT) in one patient at 450 mg/m /week. Clinical Oncology, San Francisco, CA, Two of nine DLTs were at the highest dose level. Two patients with metastatic melanoma May 12-15, 2001; 39th Annual Meeting had stable disease and were treated for 15 and 41 months, respectively.
    [Show full text]